The second funding period of the CGC (CGCII) started in 2012 after a very positive and supportive evaluation by an external committee composed of scientists from academia and industry. The MPG and the companies Bayer Crop Science, Bayer Pharma, Merck KGaA, Boehringer Ingelheim and AstraZeneca supported five newly established independent research groups.

Three of them were located in the BioMedizinZentrum (BMZ) directly adjacent to the Max Planck Institute (MPI) of Molecular Physiology in Dortmund and led by Tom Grossmann, Sven Hennig and Yaowen Wu. For scientific and infrastructural considerations the other two were located at the MPI for Molecular Biomedicine in Munster (Boris Greber) and at the University of Tubingen (Sascha Laubinger), respectively.

MEMBERS

Dr. Boris Greber

Dr. Boris Greber

Catalent
Dr. Sven Hennig

Dr. Sven Hennig

Ass. Professor of Structural Chemical Biology
Vrije Universiteit Amsterdam
Prof. Dr. Sascha Laubinger

Prof. Dr. Sascha Laubinger

University of Halle
Prof. Dr. Tom Grossmann

Prof. Dr. Tom Grossmann

Vrije Universiteit Amsterdam
Prof. Dr. Yaowen Wu

Prof. Dr. Yaowen Wu

Umeå University

SUPPORTING COMPANIES

https://www.astrazeneca.com/our-science/gothenburg.html
original
original
https://www.boehringer-ingelheim.de/
https://www.emdgroup.com/en?global_redirect=1

PARTICIPATING MAX PLANCK INSTITUTES

original
original
original
original

Web-View
Print Page
Open in new window
Estimated DIN-A4 page-width
Go to Editor View